Gilead’s Acquisition Effect on Other CAR-T Developers’ Stocks

Prohost Letters September 4, 2017

Coming Soon...
The Week in Review #3
Gilead Acquisition - Rallying by Association - Improving on Cancer Treatments...

This content is for paid subscribers.

Please click here to subscribe or here to log in.

Prohost Letters

Bellicum Pharmaceuticals Inc (BLCM), bluebird bio Inc (BLUE), CAR-T, Celgene (CELG), Cellectis (CLLS), Celyad (CYAD), CRISPR Therapeutics (CRSP), Editas Medicine Inc (EDIT), Gilead Sciences (GILD), Juno Therapeutics (JUNO), Kite Pharma - A Gilead Company, Prohost Portfolio

September 4, 2017